Over the past four decades, Biogen has been committed to translating science to meaningful advances for the MS community. Our industry-leading portfolio — backed by established safety and efficacy profiles, ongoing investment in our products, as well as our comprehensive services and solutions — enables us to offer a broad range of options to meet the ever-evolving needs of MS patients and drive greater individualized disease management.
Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Our transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis.
EMD Serono’s experience and scientific discoveries in MS date back more than 20 years. They have an ongoing commitment to improving the entire patient experience. To this end, they offer delivery devices for their therapeutic products as well as comprehensive patient education resources. It is the people living with MS or those who will be diagnosed with MS, their caregivers and healthcare providers who have been their catalyst and inspiration to continue innovating, collaborating and advocating.
CenterWell Specialty Pharmacy is an award-winning, mail-delivery pharmacy that goes beyond the typical role of a specialty pharmacy by providing valuable resources to help manage the clinical, financial and emotional complexities associated with specialty care. Through their Neuromuscular Center of Excellence, customers receive personalized and coordinated support for their MS diagnosis, including eliminating barriers to care and collaborating with providers.
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension.
At Bristol Myers Squibb, we are working to deliver meaningful solutions that address unmet needs in rheumatology, gastroenterology, dermatology and neurology. While there has been progress with medicines for immune-mediated diseases, people living with these conditions may not respond to available treatments. Many continue to endure chronic symptoms and disease progression that can take a toll on their daily life. Our goal is to restore some of what immune-medicated diseases have taken away – empowering patients and their loved ones to take back their lives.
Novartis’ purpose is to reimagine medicine to improve and extend people's lives. We use innovative science and technology to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to reward those who invest their money, time and ideas in our company.
Built on patient insights and cutting-edge science and technology, Sanofi is determined to help people living with neurological disorders by developing new treatment options and advancing patient care. With 18 years’ commitment in multiple sclerosis (MS), Sanofi has relentlessly worked to improve the lives of the 2.3 million people worldwide living with this serious, life-long neuro-degenerative disease. Since the launch of its portfolio in 2012, Sanofi has rapidly emerged as a leader in MS, bringing two therapies to patients in more than 80 countries worldwide. There is significant work left to be done, and Sanofi is committed to accelerating the development of potential treatments for MS, amyotrophic later sclerosis, and other neurological diseases.
Sandoz is a global leader in generic pharmaceuticals and biosimilars and a division of the Novartis Group. Sandoz contributes to society’s ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. That is our purpose.
We believe that the best solution for patients may not lie in a single drug but in a unique combination of medicines. TG Therapeutics was founded with one goal in mind—to leverage scientific advances in B-cell biology to develop novel treatments for patients. We’ve dedicated ourselves to this simple concept and to the study of B-cells and B-cell diseases. To achieve our goal, we search the globe looking for medicines in early research that we believe could be combined to create better treatment options for patients.